stoxline Quote Chart Rank Option Currency Glossary
  
TriSalus Life Sciences, Inc. (TLSI)
5.65  0.12 (2.17%)    02-14 16:00
Open: 5.53
High: 5.76
Volume: 19,262
  
Pre. Close: 5.53
Low: 5.53
Market Cap: 172(M)
Technical analysis
2025-02-14 4:51:54 PM
Short term     
Mid term     
Targets 6-month :  6.72 1-year :  7.85
Resists First :  5.76 Second :  6.72
Pivot price 5.35
Supports First :  4.99 Second :  4.53
MAs MA(5) :  5.59 MA(20) :  5.26
MA(100) :  4.5 MA(250) :  6.29
MACD MACD :  0.2 Signal :  0.2
%K %D K(14,3) :  86.5 D(3) :  87.5
RSI RSI(14): 64.7
52-week High :  10.42 Low :  3.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TLSI ] has closed below upper band by 18.3%. Bollinger Bands are 0.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.77 - 5.8 5.8 - 5.83
Low: 5.45 - 5.49 5.49 - 5.53
Close: 5.59 - 5.65 5.65 - 5.71
Company Description

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Headline News

Fri, 14 Feb 2025
Lake Street Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy Recommendation - Nasdaq

Thu, 13 Feb 2025
TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Analysts at Lake Street Capital - MarketBeat

Mon, 10 Feb 2025
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Buys $33,900.00 in Stock - MarketBeat

Thu, 06 Feb 2025
Trisalus Life Sciences CFO buys $33,900 in common stock - Investing.com

Mon, 03 Feb 2025
Trisalus Life Sciences Announces Key Appointments To Board Of Directors -February 03, 2025 at 05:03 pm EST - Marketscreener.com

Mon, 03 Feb 2025
TriSalus Life Sciences, Inc. Announces Drawdown of $10 Million Tranche Under Credit Agreement with Orbimed - Marketscreener.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 30 (M)
Shares Float 21 (M)
Held by Insiders 43.3 (%)
Held by Institutions 17.2 (%)
Shares Short 58 (K)
Shares Short P.Month 51 (K)
Stock Financials
EPS -1.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.99
Profit Margin -219.8 %
Operating Margin -111 %
Return on Assets (ttm) -133.2 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 59.7 %
Gross Profit (p.s.) 0.71
Sales Per Share 0.81
EBITDA (p.s.) -1.7
Qtrly Earnings Growth 0 %
Operating Cash Flow -55 (M)
Levered Free Cash Flow -53 (M)
Stock Valuations
PE Ratio -2.95
PEG Ratio 0
Price to Book value -5.77
Price to Sales 6.96
Price to Cash Flow -3.16
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android